IXHLNasdaqPharmaceutical PreparationsFiscal year ends June 30
Incannex Healthcare Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 25, 2026
$2.76−0.06 (-2.13%)
Close on Oct 19, 2026
- Market cap
- $33.89M
- P/E (TTM)
- –
- Dividend yield
- –
Incannex Healthcare Inc. revenue by segment
By business segment
| Revenue | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Consolidated [Member] | – | – | $1.90M | $1.32M | – | – |
| Oral and Dental Devices [Member] | – | – | – | $718.66K | – | – |
| Medicinal Cannabis [Member] | – | – | $1.90M | $604.88K | – | – |
| Cannabinoid Products [Member] | – | – | $1.90M | – | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Incannex Healthcare's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.